Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes for Two Conditioning Regimens Evaluated

Biol Blood Marrow Transplant; ePub 2017 Jan 17; Ali, et al

Publish date:: February 1, 2017

Two types of alloHCT conditioning regimens produced similar outcomes in a study involving 71 individuals.

Participants had either acute myeloid leukemia or myelodysplastic syndrome. Investigators compared outcomes in patients who received conditioning via either busulfan and fludarabine (BuFlu; n=33) or fludarabine and 400 cGy total body irradiation (FluTBI; n=38). Among the results:

Patients receiving BuFlu had more red blood cell transfusions and took longer to achieve platelet recovery.
Acute and chronic graft-versus-host disease rates were similar in both groups, as were quality of life measures.
2-year outcomes for relapse, non-relapse mortality, relapse-free survival, and overall survival were also similar in both groups.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,